Condition: Lynch Syndrome · Colon Cancer · Colon Neoplasm · Sponsor: Ann-Sofie Backman
Multicenter, multinational, randomized, 2-arm, double-blind, phase II clinical study with 2000mg mesalamine, or placebo for prevention of colorectal neoplasia in Lynch Syndrome patients during and following daily intake for 2 years.
This description comes directly from the study's public registry record.
Ann-Sofie Backman, MD PhD · 707515285 · ann-sofie.backman@ki.se
Always discuss trial participation with your own doctor first.
| Aalborg University Hospital | Aalborg, Denmark | Not Yet Recruiting |
| Hvidovre Hospital | Hvidovre, Denmark | Recruiting |
| Sahlgrenska University Hsospital | Gothenburg, Gothenburg, Sweden | Recruiting |
| Skåne University Hospital | Malmö, Skåne County, Sweden | Recruiting |
| Ersta Hospital/Ersta Diakoni | Stockholm, Sweden | Recruiting |
| Karolinska University Hospital | Stockholm, Sweden | Active Not Recruiting |
| Norrland University Hospital | Umeå, Sweden | Recruiting |
| Akademiska hospital | Uppsala, Sweden | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04920149